Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Rocket Pharmaceuticals (RCKT) over the last 7 years, with Q3 2025 value amounting to $111.6 million.

  • Rocket Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1849.29% to $111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year increase of 1849.29%. This contributed to the annual value of $94.8 million for FY2024, which is 1285.43% up from last year.
  • Rocket Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $111.6 million in Q3 2025, which was up 1849.29% from $111.0 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $111.6 million during Q3 2025, and registered a low of $61.6 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $80.5 million (2023), whereas its average is $81.7 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 374.48% in 2022, then surged by 2479.87% in 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $63.2 million in 2021, then grew by 7.77% to $68.1 million in 2022, then grew by 23.27% to $84.0 million in 2023, then grew by 12.85% to $94.8 million in 2024, then rose by 17.68% to $111.6 million in 2025.
  • Its last three reported values are $111.6 million in Q3 2025, $111.0 million for Q2 2025, and $110.1 million during Q1 2025.